← Issue №12/ week of Sep 20, 2026/ the whole section, in full

Colorectal, in full.

All 2 Colorectal papers in this issue, as full cards, ranked by clinical utility. The issue page carries the strongest few; this is the section, whole.

Sections this issue
Filter

All 2, in full

most clinically useful first · the 1 the issue led with is ruled in green
Colorectal rct · n=10,799 · Sep 17, 2026 · NEJM · IF 84.5

Colonoscopy Intervals and Colorectal Cancer Incidence after Adenoma Removal.

Practice-changingcolorectal cancercolorectal cancer screeningadenoma
Clinical takeawayConsider extending the first surveillance colonoscopy interval to 5 years (vs 3 years) for patients with high-risk adenomas (≥1 adenoma ≥10 mm, high-grade dysplasia, villous growth, or 3-10 adenomas), pending final 10-year results.
What it found5-year cumulative incidence of colorectal cancer was 0.77% with 5-year surveillance vs 0.82% with 3-year surveillance (difference -0.05 percentage points; noninferiority margin 0.7 percentage points).
ContextChallenges current guideline recommendations for 3-year surveillance in high-risk adenoma patients, suggesting noninferiority of a 5-year interval in this interim analysis.
Measured against the standard of care· USMSTF 2020 (Gupta et al., post-polypectomy surveillance) / USMSTF 2026 (Rex et al., Serrated Polyposis Syndrome consensus statement)

General post-polypectomy surveillance still follows USMSTF 2020 (Gupta et al.), which has not been replaced: 1-2 tubular adenomas <10 mm, 7-10 years; 3-4 tubular adenomas <10 mm, 3-5 years; 5-10 tubular adenomas <10 mm, any adenoma ≥10 mm, or an adenoma with tubulovillous/villous histology or high-grade dysplasia, 3 years; >10 adenomas, 1 year with polyposis evaluation. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

General post-polypectomy surveillance still follows USMSTF 2020 (Gupta et al.), which has not been replaced: 1-2 tubular adenomas <10 mm, 7-10 years; 3-4 tubular adenomas <10 mm, 3-5 years; 5-10 tubular adenomas <10 mm, any adenoma ≥10 mm, or an adenoma with tubulovillous/villous histology or high-grade dysplasia, 3 years; >10 adenomas, 1 year with polyposis evaluation. For serrated polyps: 1-2 SSLs <10 mm, 5-10 years; 3-4 SSLs <10 mm or a hyperplastic polyp ≥10 mm, 3-5 years; an SSL ≥10 mm, an SSL with dysplasia, or a traditional serrated adenoma, 3 years. When findings are mixed, use the shortest interval indicated. Before applying an interval, confirm complete resection and adequate prep. Piecemeal resections get a site check, and malignant (T1) polyps go to a tumor-board pathway. Serrated polyposis syndrome (SPS) is now governed by a separate USMSTF consensus statement (Rex et al., published simultaneously in Gastroenterology, Am J Gastroenterol and GIE on 2026-09-30). It has 11 recommendations. Diagnose SPS with the 2019 WHO criteria, which count the size, cumulative lifetime number and location of serrated polyps. Until SPS is diagnosed, record the number, size and location of serrated polyps in every colonoscopy report. SPS colonoscopy should be done by endoscopists with documented adequate SSL detection, using high-definition white light with or without chromoendoscopy. Without concurrent CRC, endoscopy is preferred over surgery for primary management. If the polyp burden cannot be managed endoscopically, refer to an advanced endoscopic resection expert before surgery. Resect SSLs and hyperplastic polyps by cold snare, with submucosal injection for larger lesions. Do clearance colonoscopy at 3-6 months, then surveil every 1-2 years. Consider 3-year intervals if the burden is greatly reduced at surveillance. First-degree relatives start colonoscopy at age 40, or 10 years before the youngest CRC diagnosis in the family, or 5 years before the youngest SPS diagnosis, whichever comes first. SPS has no established genetic basis, so germline testing is recommended only when concurrent non-serrated polyps suggest a heritable syndrome. Lynch, FAP/AFAP and MAP criteria still trigger genetic evaluation.

USMSTF 2020 (Gupta et al., post-polypectomy surveillance) / USMSTF 2026 (Rex et al., Serrated Polyposis Syndrome consensus statement) · reviewed 2026-10-11 ↗
Jover R … EPoS Study Group · New England Journal of Medicine · IF 84.5 · PubMed ↗Permalink
Colorectal retrospective · n=6,697 · Sep 14, 2026 · Dig Liver Dis · IF 4.2

The influence of tumor side, sex, and screening on colon cancer stage and survival: a 25-year population-based study.

New evidenceepidemiologycolorectal cancercolorectal cancer screeningdysplasia
Clinical takeawayConsider prioritizing FIT-based screening for older patients, particularly women, and men with advanced-stage disease, given the increased incidence and worse prognosis of right-sided colon cancer in these groups.
What it foundRight-sided colon cancer incidence increased with aging (p ≤ 0.001) and was associated with female sex (OR 1.40, 95% CI 1.27-1.54), advanced stage in men (node-positive: OR 1.54, 95% CI 1.17-2.02; metastatic: OR 1.47, 95% CI 1.06-2.03), and worse prognosis in men (HR 1.16, 95% CI 1.01-1.34) compared to left-sided colon cancer.
ContextConfirms and refines prior evidence on the divergent behavior of right- and left-sided colon cancer, emphasizing the role of tumor side, sex, and screening impact in stage and survival outcomes in older patients, women, and men with advanced-stage disease.
Measured against the standard of care· USMSTF 2017 (Rex et al., Gastroenterology) + USMSTF 2022 focused update on age (Patel et al., Gastroenterology 2022;162:285-299) / ACS 2026 (CA Cancer J Clin)

Decision at stakethe choice of colorectal cancer screening modality

… Multi-Society Task Force (2017 guideline, revised by the 2022 focused update on age to start and stop): offer average-risk colorectal cancer screening to everyone aged 45-75. … The American Cancer Society's May 2026 guideline agrees on the 45-75 range, no screening after 85, and colonoscopy as the preferred option. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

U.S. Multi-Society Task Force (2017 guideline, revised by the 2022 focused update on age to start and stop): offer average-risk colorectal cancer screening to everyone aged 45-75. Screening at 45-49 is a weaker recommendation than at 50-75. Colonoscopy every 10 years and annual FIT are the Tier 1 cornerstones. Tier 2 alternatives are multi-target stool DNA every 3 years, CT colonography every 5 years, and flexible sigmoidoscopy every 5-10 years. Capsule colonoscopy every 5 years is Tier 3. Any abnormal non-colonoscopy test requires a diagnostic colonoscopy, and a stool test should not be offered to a patient who would decline follow-up colonoscopy. Patients who are up to date with negative prior screening, particularly a high-quality colonoscopy, may consider stopping at 75 or when life expectancy is under 10 years. Decisions at 76-85 are individualized by health and prior screening, and screening after 85 is not recommended. The American Cancer Society's May 2026 guideline agrees on the 45-75 range, no screening after 85, and colonoscopy as the preferred option. It adds the next-generation mt-sDNA test and the multitarget stool RNA test (ColoSense), both every 3 years, and it adds an FDA-approved blood-based cfDNA test (Shield) only for people who decline or do not complete visual or stool screening. ACS says a positive stool or blood test should be followed by colonoscopy, preferably within 6 months. The 2026 ASGE paper on follow-up after an abnormal stool test is an implementation review (navigation, tracking, direct-access colonoscopy), not a new screening guideline.

USMSTF 2017 (Rex et al., Gastroenterology) + USMSTF 2022 focused update on age (Patel et al., Gastroenterology 2022;162:285-299) / ACS 2026 (CA Cancer J Clin) · reviewed 2026-10-11 ↗
Kayali S … Laghi L · Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · IF 4.2 · PubMed ↗Permalink
← Back to issue №12 Every section of this issue is one click away, at the top of this page. Follow Colorectal by RSS